MEDICARE COVERAGE GUIDELINES
BIPAP/RAD Therapy

Types of BiPAP (Bi-Level Positive Airway Pressure) / RAD (Respiratory Assist Devices)

- **E0470 –** Respiratory assist device, Bi-Level pressure capable, **without** backup rate feature, used with noninvasive interface
- **E0471** - Respiratory assist device, Bi-Level pressure capable, **with** backup rate feature, used with noninvasive interface

E0470

- Beneficiary meets all criteria listed for Positive Airway Device (E0601), AND
- E0601 PAP device has been tried and proven ineffective based on a therapeutic trial.
- Sleep test

E0470 and E0471

Central Sleep Apnea or Complex Sleep Apnea

Prior to initiating therapy, a complete facility-based, attended sleep study was performed and documented:

- Diagnosis of either CSA or CompSA, AND:
- Significant improvement of the sleep associate hypoventilation with is of an E0470 or E0471 on the settings the physician prescribed for initial use at home while breathing the usual FIO2.

Severe COPD E0470

- Arterial blood gas PaCO2 is ≥ 52 mm Hg while the beneficiary is awake breathing the prescribed FIO2, AND
- Sleep oximetry study demonstrates oxygen saturation ≤ 88% for ≥ 5 cumulative minutes of nocturnal recording time (minimum of 2 hours) done while breathing oxygen at 2 LPM on the beneficiary's usual FIO2 (whichever is higher)

Severe COPD E0471

Situation 1: An E0471 started anytime after a period of initial use of E0470 is covered if:

- Arterial blood gas PaCO2 is ≥ 7 mm Hg while the beneficiary is awake breathing the prescribed FIO2, AND
- Facility-based sleep study demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes of nocturnal recording time (minimum of 2 hours) while using E0470 that is not caused by obstructive airway events (AHI < 5).

Situation 2: E0471 will be covered no sooner than 61 days after initial use of the E0470 if:

- Arterial blood gas PaCO2 is ≥ 52 mm Hg while the beneficiary is awake breathing the prescribed FIO2, AND
- Sleep oximetry while breathing with the E0470 demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes of nocturnal recording time (minimum of 2 hours) done while breathing oxygen at 2 LPM on the beneficiary's usual FIO2 (whichever is higher)

Hypoventilation Syndrome E0470

- Arterial blood gas PaCO2 is ≥ 45 mm Hg while the beneficiary is awake breathing the prescribed FIO2, AND
- Spirometer shows an FEV1/FVC ≥ 70% ad ab FEV1 is ≥50% of predicted, AND
- Facility-based sleep study demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes of nocturnal recording time (minimum of 2 hours) while using E0470 that is not caused by obstructive airway events (AHI < 5).

Hypoventilation Syndrome E0471

- A covered E0470 is being used, AND
- Spirometer shows an FEV1/FVC ≥ 70% ad ab FEV1 is ≥ 50% of predicted, AND
- Facility based sleep study demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes of nocturnal recording time (minimum of 2 hours) while using E0470 that is not caused by obstructive airway events (AHI < 5 while using E0470).

If the beneficiary failed 90 day compliance

- Face to face re-evaluation is needed to determine why the patient failed in compliance for PAP Therapy.
- Repeat Sleep test in a facility-based setting.

Replacement of BiPAP (E0470 or E0471)

Following the 5 year reasonable useful lifetime (RUL), there must be:

- F2F that documented that the beneficiary continues to use and benefit from the device, AND
- A new prescription